{"disease":{"id":"cryptococcosis","name":"Cryptococcosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"isavuconazonium","indication_name":"Cryptococcosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cresemba","generic_name":"ISAVUCONAZONIUM","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Azole Antifungal","quality_score":60,"revenue":null,"mechanism":"Isavuconazonium sulfate is a prodrug that converts to isavuconazole, an azole antifungal."},{"drug_id":"amphotericin-b","indication_name":"Cryptococcosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Pulmonary cryptococcosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"flucytosine","indication_name":"Systemic Cryptococcosis Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05707156","title":"Prospective Observational Study on the Incidence of Opportunistic Fungal Infections","phase":"","overall_status":"COMPLETED","enrollment_count":12032,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT03267407","title":"Vietnam Cryptococcal Retention in Care Study - Version 2.1","phase":"","overall_status":"UNKNOWN","enrollment_count":1184,"lead_sponsor_name":"National Hospital for Tropical Diseases, Hanoi, Vietnam","has_results":false},{"nct_id":"NCT04554875","title":"Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT00001352","title":"Fungal Infection Susceptibility","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00001701","title":"Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03993093","title":"Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre","phase":"","overall_status":"COMPLETED","enrollment_count":257,"lead_sponsor_name":"Singh, Ranjan Kumar, M.D.","has_results":false},{"nct_id":"NCT04033718","title":"Inpatient Package to Reduce HIV and AIDS-related Death in Zambia","phase":"NA","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT03002012","title":"Cryptococcal Antigen Screening Plus Sertraline","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"University of Minnesota","has_results":true}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}